The 4 references in paper A. Kotov S., Yu. Tokareva V., V. Lutsik N., M. Panteleeva V., A. Shatalin V., E. Mukhina V., M. Bunak S., O. Andryukhina M., А. Котов С., Ю. Токарева В., В. Луцик Н., М. Пантелеева В., А. Шаталин В., Е. Мухина В., М. Бунак С., О. Андрюхина М. (2018) “Расстройство из спектра оптиконевромиелита в детском возрасте (клинический случай) // Neuromyelitis optica spectrum disorder in childhood (a case report)” / spz:neicon:rjdn:y:2017:i:4:p:56-62

1
Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange. Mult Scler 2016;22(2):185–92. DOI: 10.1177/1352458515581438.
(check this in PDF content)
2
Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 2009;256(11):1891–8. DOI: 10.1007/s00415-009-5171-x. 5. Coutinho A.E.,
(check this in PDF content)
3
Huston D.P. Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch Neurol 1988;45(1):27–30. PMID: 3276298. 10. Mandler R.N., Ahmed W.
(check this in PDF content)
4
Weinshenker B.G. Neuromyelitis optica. Curr Opin Neurol 2007;20(3):255–60. DOI: 10.1097/WCO.0b013e32814f1c6b. 12. Oh J., Levy M. Neuromyelitis optica: an antibody-mediated di
(check this in PDF content)